Jack Talley discusses his company with William Dawson of LifeTech Capital
second Q it is. More interesting (?) is to note the unspecific time table for an agreement on NP-1. Was it "any point"? Don't remember.
There are several signatures making calculations on Epicept in Sweden right now. I think it is fair to say that there are three main groups:
+ The ones trying to predict near time cash flow from Ceplene plus upfronts + Those who just counts the upfronts and hold Ceplene as a nice surprise + The ones that involves figures from sales also in the US market.
I like the approach in the midle, having Ceplenes implementation by Meda as a nice surprise. My point about the NP-1 agreement is that the investor do not have to have an more or less exact estimation of the figures coming through that deal. It is enough to understand that it is a huge deal making Epicept carried to peak-sales figures from Ceplene.
After the agreement the volume in Sweden have been far over average . The whole stock of shares (eng.?) was traded after the first 5 days in Sthlm!
After the Nasdaq debacle is behind us (todays release) I think we will have nice updates on the owner list.